

(12) PATENT
(19) AUSTRALIAN PATENT OFFICE

(11) Application No. **AU 199913113 B2**
(10) Patent No. **735094**

(54) Title
Interferon immunotherapy

(51)⁶ International Patent Classification(s)
A61K 038/21

(21) Application No: **199913113** (22) Application Date: **1998 .11 .06**

(87) WIPO No: **WO99/24060**

(30) Priority Data

(31) Number	(32) Date	(33) Country
60/064618	1997 .11 .07	US

(43) Publication Date : **1999 .05 .31**

(43) Publication Journal Date : **1999 .07 .29**

(44) Accepted Journal Date : **2001 .06 .28**

(71) Applicant(s)
Mayo Foundation for Medical Education and Research

(72) Inventor(s)
Svetomir N. Markovic

(74) Agent/Attorney
CALLINAN LAWRIE,Private Bag 7,KEW VIC 3101

(56) Related Art
US 4846782

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



13113/99

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 38/21	A1	(11) International Publication Number: WO 99/24060 (43) International Publication Date: 20 May 1999 (20.05.99)
(21) International Application Number: PCT/US98/23639 (22) International Filing Date: 6 November 1998 (06.11.98) (30) Priority Data: 60/064,618 7 November 1997 (07.11.97) US (71) Applicant: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH [US/US]; 200 First Street S.W., Rochester, MN 55905 (US). (72) Inventor: MARKOVIC, Svetomir, N.; 4223 Manor View Drive N.W., Rochester, MN 55901 (US). (74) Agent: ELLINGER, Mark, S.; Fish & Richardson P.C., P.A., Suite 3300, 60 South Sixth Street, Minneapolis, MN 55402 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> IP AUSTRALIA 24 MAY 1999 RECEIVED
(54) Title: INTERFERON IMMUNOTHERAPY (57) Abstract Use of an α-interferon composition in the manufacture of a medicament for reducing the recurrence of a resectable malignant tumor is described. Use of an α-interferon composition in the manufacture of a medicament for treating a human patient having a non-resectable malignant tumor also is described. An article of manufacture combines an α-interferon composition within a packaging material and a package label or insert indicating that administration of an immunostimulatory dosage of an α-interferon composition followed by surgical resection of a malignant tumor can be effective for treating a human patient having the malignant tumor.		

- 1 -

INTERFERON IMMUNOTHERAPYField of the Invention

5 The invention relates to administering interferon. More particularly, the invention relates to administering interferon preoperatively and administering interferon for treating cancer.

Background of the Invention

10 Interferons (IFNs) are immunologically active proteins produced by mammalian cells following infectious or cytokine stimuli. As biologically active substances, IFNs have three broad modes of action: direct antiproliferative effects on tumor cells, direct
15 antiviral effects inhibiting viral replication, and immunomodulatory (also referred to as immunostimulatory) effects on the mammalian immune system. Kalvakolanu, D.V., & Borden, E.C., Cancer Investigation, 14:25 (1996).

Interferons are generally divided into three
20 species (IFN- α , IFN- β and IFN- γ) and two types according to their structural and functional characteristics. Type I IFNs (IFN- α and IFN- β) are produced following viral infection and have dosage dependent anti-tumor, anti-viral and immunomodulatory properties. Kopp, C.W. et
25 al., Cancer Chemotherapy and Biological Response Modifiers, 15:226 (1994); Agrwala, S.S., & Kirkwood, M.J., Oncology, 51:129 (1994). Type II IFNs (IFN- γ) are produced by T lymphocytes following lymphokine stimulation. Kalvakolanu, V.D. & Borden, C.E., Cancer
30 Investigation, 14:25 (1996). Type II IFNs have predominantly an immunomodulatory function with relatively less antiviral or antitumor activity.

Announced as a potential cure for cancer, IFNs have been used for treating several disease states,

- 2 -

including chronic hepatitis C, multiple myeloma, multiple sclerosis, melanoma and CML. Kalvakolanu, V.D. & Borden, C.E., Cancer Invest., 14:25 (1996); Mughal, T.I. & Goodman, J.M., Ann. Onc., 6:537 (1995); Ucar, R. et al., Ann. Allergy, Asthma & Immun., 75:377 (1995); Sapiro, R.J. et al., Am. J. Nephrol., 15:343 (1995); Sharara, A.I. et al., Ann. Int. Med., 125:658 (1996).

The current standard of care for human IFN cancer therapies utilizes antiproliferative IFN dosages. These dosages are maximum tolerable dosages at about 10-20 million U/m² per day. Kirkwood, J. Clin. Oncol., 14:7-17 (1996). IFN treatments have had limited effectiveness against solid tumors. Moreover, antiproliferative IFN dosages can suppress multiple immune system parameters including NK lymphocytes. Maluish et al., J. Immun., 131:503 (1983).

Cancer therapy also includes surgical resection or debulking of a tumor mass. Surgical excision is not typically curative because surgery does not combat minimal residual disease. Minimal residual disease refers to cancer cells that have dissociated from a primary tumor either prior to surgery or during surgical resection. Current imaging techniques, such as CT scans and x-rays, are unable to detect these dissociated cancer cells. It is believed these dissociated cancer cells lead to primary tumor recurrence. Also, these undetected cells are the nidus of metastatic disease, which is considered the most significant component of cancer mortality.

To increase the cancer therapy success rate, chemical and immunological compounds are used in conjunction with surgical resection. Effective combined therapies are difficult to develop. One possible explanation for the lack of effective therapies is the phenomenon of transient post-operative immunological

- 3 -

deficiencies observed for surgical patients. Slade et al., Surgery, 78: 363 (1975); Lee, Y.T., J. Surg. Onc., 9:425-430 (1977). This postoperative immunosuppression increases a patient's susceptibility to post-operative infections, tumor reoccurrence and metastasis. As a result, the medical community is still searching for effective cancer therapies.

Summary of the Invention

In one aspect, the invention is a method for
10 treating a human patient having a malignant tumor by administering an immunostimulatory dosage of an α -interferon composition to the patient, then surgically resecting the malignant tumor. The invention also features a use of an α -interferon composition in the
15 manufacture of a medicament for the treatment of a human patient having a resectable malignant tumor. The use can include administering an immunostimulatory dosage of the medicament containing an α -interferon composition to the patient, then surgically resecting the malignant tumor.
20 In another embodiment, a use in a therapeutic preparation of an α -interferon composition for the treatment of a human patient having a resectable malignant tumor can include administering an immunostimulatory dosage of the therapeutic preparation to the patient, then surgically
25 resecting the malignant tumor.

The immunostimulatory dosage may be about 3,000,000 U/m² of α -interferon per day or less. The immunostimulatory dosage can also be set at about 1,000,000 U/m² per day or less, about 500,000 U/m² per day
30 or less, about 250,000 U/m² per day or less, or about 100,000 U/m² per day or less. The immunostimulatory dosage may also be about 3,000,000 U/m² of α -interferon per day, about 1,000,000 U/m² per day, about 500,000 U/m² per day, about 250,000 U/m² per day, or about 100,000 U/m²

- 4 -

per day. In one embodiment, the dosage is administered once per day, typically for about five days prior to resecting the malignancy.

The immunostimulatory dosage can be selected to
5 increase a patient's NK lymphocyte cytotoxicity at least about 50% above the NK lymphocyte cytotoxicity level that the patient had before administering the α -interferon composition. Preferably, the immunostimulatory dosage increases a patient's NK lymphocyte cytotoxicity at least
10 about 75% above the NK lymphocyte cytotoxicity level that the patient had before administering the α -interferon. The NK lymphocyte cytotoxicity can be measured at an effector to target cell ratio from about 15:1 to about 50:1. Other effector cell to target cell ratios can
15 include 3:1, 6:1, 10:1, 12:1, 25:1, 50:1, 75:1, and 100:1. The immunostimulatory dosage may also increase B-lymphocyte and/or T-lymphocyte activation. The immunostimulatory dosage may also increase B-lymphocyte and/or T-lymphocyte function.

20 The method is useful for treating solid tumors, including without limitation breast cancer, lung cancer, pancreatic cancer, brain cancer, prostate cancer, ovarian cancer, uterine cancer, renal cancer, melanoma and other solid tumors. The method is particularly useful for
25 treating melanoma and renal carcinoma tumors. In another embodiment, the solid tumor is an early-stage solid tumor.

In another aspect, the invention is a method for preventing post-operative infections by administering an
30 immunostimulatory dosage of an α -interferon composition to a human before surgery. In one embodiment, a use of an α -interferon composition in the manufacture of a medicament for preventing post-operative infection can include administering an immunostimulatory dosage of the
35 medicament containing an α -interferon composition to a

- 5 -

human before surgery. In another embodiment, a use in a therapeutic preparation of an α -interferon composition for preventing post-operative infection can include administering an immunostimulatory dosage of an α -
5 interferon composition to a human before surgery.

In another aspect, the invention is an article of manufacture encompassing packaging material and an α -interferon composition contained within the packaging material. The packaging material includes a label or
10 package insert indicating that administration of an immunostimulatory dosage of the α -interferon composition followed by surgical resection of a malignant tumor can be effective for treating a human patient having a malignant tumor.

15 In another aspect, the invention features an article of manufacture containing packaging material and an α -interferon composition contained within the packaging material. The packaging material can contain a label or package insert indicating that administration of
20 an immunostimulatory dosage of the α -interferon composition in conjunction with treating the patient using effective non-surgical medical methodologies for diminishing the malignant tumor can be effective for treating a human patient having the malignant tumor.

25 In another aspect, the invention features a method for treating a human patient having a non-resectable malignant tumor by administering an immunostimulatory dosage of an α -interferon composition to the patient and treating the patient using effective non-surgical medical
30 methodologies to diminish the tumor. In one embodiment, a use of an α -interferon composition in the manufacture of a medicament for the treatment of a human patient having a non-resectable malignant tumor can include administering an immunostimulatory dosage of the
35 medicament containing an α -interferon composition to the

- 6 -

patient and treating the patient with effective non-surgical medical methodologies to diminish the tumor. In another embodiment, a use in a therapeutic preparation of an α -interferon composition for the treatment of a human patient having a non-resectable malignant tumor can include administering an immunostimulatory dosage of an α -interferon composition to the patient and treating the patient with effective non-surgical medical methodologies to diminish the tumor. In another embodiment, the medical methodologies include radiation therapy.

The immunostimulatory dosage may be about 3,000,000 U/m² of α -interferon per day or less. The immunostimulatory dosage can also be set at about 1,000,000 U/m² per day or less, about 500,000 U/m² per day or less, about 250,000 U/m² per day or less, or about 100,000 U/m² per day or less. The immunostimulatory dosage may also be about 3,000,000 U/m² of α -interferon per day, about 1,000,000 U/m² per day, about 500,000 U/m² per day, about 250,000 U/m² per day, or about 100,000 U/m² per day. In one embodiment, the dosage is administered once per day, typically for about five days prior to resecting the malignancy.

The immunostimulatory dosage can be selected to increase a patient's NK lymphocyte cytotoxicity at least about 50% above the NK lymphocyte cytotoxicity level that the patient had before administering the α -interferon composition. Preferably, the immunostimulatory dosage increases a patient's NK lymphocyte cytotoxicity at least about 75% above the NK lymphocyte cytotoxicity level that the patient had before administering the α -interferon. The NK lymphocyte cytotoxicity can be measured at an effector to target cell ratio from about 15:1 to about 50:1. Other effector cell to target cell ratios can include 3:1, 6:1, 10:1, 12:1, 25:1, 50:1, 75:1, and 100:1. The immunostimulatory dosage may also increase B-

- 7 -

lymphocyte and/or T-lymphocyte activation. The immunostimulatory dosage may also increase B-lymphocyte and/or T-lymphocyte function.

The method is useful for treating solid tumors, including without limitation breast cancer, lung cancer, pancreatic cancer, brain cancer, prostate cancer, ovarian cancer, uterine cancer, renal cancer, melanoma and other solid tumors. The method is particularly useful for treating melanoma and renal carcinoma tumors. In another embodiment, the solid tumor is an early-stage solid tumor.

Advantages of the invention include eliminating, or inhibiting the progress of, minimal residual disease, which includes preventing both primary tumor regrowth and metastatic disease following surgical resection or other medical treatments.

Unless otherwise defined, all technical and scientific terms and abbreviations used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. All publications, patent applications, patents and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control. Other features and advantages of the invention will be apparent from the following description of the preferred embodiments and from the claims.

Brief Description of the Drawings

FIG. 1 is a graph depicting the increase in NK lymphocyte cytotoxicity levels at effector:target cell

- 8 -

ratios of 3:1 and 25:1 after administering a low dosage of ALFERON-N (TM) to a human volunteer in vivo.

FIG. 2 is a graph depicting the increase in NK lymphocyte cytotoxicity levels at a variety of effector:target cell ratios after administering a low dosage of ALFERON-N (TM) to a human volunteer in vivo.

Detailed Description

The present invention involves administering IFN- α to patients prior to surgically resecting a resectable malignancy, for reducing the risk of primary tumor recurrence, and for preventing the occurrence of metastases. The invention also involves administering IFN- α to patients prior to surgery to prevent post-operative infections and administering IFN- α to patients undergoing alternative methodologies for reducing, diminishing or eliminating solid malignancies.

Interferons can stimulate several cell types including Natural Killer (NK) lymphocytes. NK lymphocytes are a primary component of the mammalian immune system's defenses against infection and neoplastic diseases, and possess antitumor, antiviral and antibacterial properties. Administering mice IFN- α and IFN- β enhances the cytotoxic activities of NK lymphocytes. Markovic, S.N. & Murasko, D.M., Cancer Research, 51:1124 (1991). Stimulating murine NK lymphocyte activity by itself, however, is insufficient to eliminate established tumors. Markovic, S.N. & Murasko, D.M., Int. J. Cancer, 45:788 (1990). NK lymphocytes in anesthetized mice are transiently unresponsive to IFN- α and IFN- β . Markovic, S.N. and Murasko, D.M., Clin. Immun. & Immunopath., 60:181-189 (1991), Markovic, S.N. & Murasko, D.M., Clin. Immun. & Immunopath., 56:202-209 (1990), Markovic, S.N. and Murasko, D.M., Cellular Immun., 151:474-480 (1993).

- 9 -

Combining surgical debulking of a primary tumor with neo-adjuvant administration of a mixture of IFN- α and IFN- β (IFN- α/β) in mice implanted with B16F10L tumor cells was successful in inducing complete remission/cure in more than 60% of the test mice that otherwise would have died of lung metastases. Markovic, S.N. & Murasko, D.M., Int. Journal of Cancer, 45:788 (1990). The observed antitumor effect of neoadjuvant IFN- α/β therapy was mediated in mice by NK lymphocytes, which remained stimulated following surgery. Markovic, S.N. & Murasko, D.M., Cancer Research, 51:1124 (1991). Administering IFN- α/β postoperatively, on the other hand, was ineffective.

By identifying an IFN- α immunostimulatory dosage in humans, a combined therapy utilizing preoperative IFN- α therapy and surgical tumor resection can be used for treating resectable malignant tumors. As used herein, immunostimulatory dosages (ISD) are IFN- α dosages that increase NK lymphocyte cytotoxicity levels in a human.

Resectable malignant tumors include any solid tumor. Solid tumors, as used herein, refers to any malignant tumor that grows as a mass. Preferably, the resectable malignant tumor is an early-stage solid tumor. Early-stage solid tumors are solid tumors for which surgical resection results in complete removal of detectable tumor tissue in a patient as measured by current imaging techniques, e.g., CT scans or chest x-rays. Illustrative examples of resectable solid tumors include breast cancer, lung cancer, pancreatic cancer, brain tumors, prostate cancer, ovarian cancer, uterine cancer, renal cancer, melanoma and other solid tumor malignancies. Although each tumor type may be amenable to surgical resection at different stages of growth, these stages are known.

- 10 -

Under certain circumstances, a localized malignant tumor may not be amenable to surgical resection. For example, the tumor may be in a location in the body that is not amenable to surgery or may not be at an appropriate growth stage. A solid tumor that is not amenable to surgical resection may be treated using a combined therapy utilizing immunostimulatory dosages of IFN- α and alternative tumor therapies. For example, immunostimulatory dosages of IFN- α can be combined with radiation therapy. The radiation therapy may reduce, diminish, or eliminate the solid tumor mass. Preferably, the solid tumor is an early-stage solid tumor.

A human can be administered an IFN- α composition prior to surgical resection or debulking of the tumor mass. The preoperative timing of administration and the ISD dosages of IFN- α can be designed to be effective for stimulating a patient's immune system and maintaining this stimulation following surgery. Such a therapy may provide a short, effective, low-toxicity, safe, out-patient based, and cost-effective method for treating resectable malignant tumors.

Surgical techniques to resect or debulk tumors are known, and include any accepted surgical technique useful for tumor removal.

The IFN- α composition may be one or more individual IFN- α s derived from any source and may include natural and/or recombinant IFN- α . The IFN- α composition can include, for example, a single isolated IFN- α or one or more IFN- α s that are combined to form a mixture of IFN- α s. Natural IFN- α compositions are IFN- α s that are isolated from animals, tissues or cells that naturally produce IFN- α . Recombinant IFN- α compositions are IFN- α s produced using recombinant DNA technologies.

An illustrative example of a natural IFN- α composition in accordance with the invention is the

- 11 -

natural IFN- α composition sold under the trade designation ALFERON-N (TM), which is a mixture of IFN- α s ranging in molecular weight from 16 KD to 27 KD (approximately 166 amino acids). ALFERON-N (TM) is
5 manufactured from pooled units of human peripheral blood leukocytes that have been induced with Sendai virus to produce IFN- α . ALFERON-N (TM) is available from Interferon Sciences, Inc., 783 Jersey Ave., New Brunswick, NJ 08901. ALFERON-N (TM) is supplied as an
15 injectable solution containing 5×10^6 U/ml IFN- α along with 3.3 mg/ml phenol and 1 mg/ml human albumin in a pH 7.4 maintained phosphate-buffered saline solution (8.0 mg/ml sodium chloride, 1.74 mg/ml sodium phosphate dibasic, 0.2 mg/ml potassium phosphate monobasic, and 0.2
20 mg/ml potassium chloride). ALFERON-N (TM) should be stored at 2-8°C and must not be frozen or shaken.

Illustrative examples of recombinant IFN- α s include the IFN- α s sold under the trade designation INTRON-A (TM) available from Schering-Plough Corporation
20 and ROFERON-A (TM) available from Hoffman-La Roche Corporation.

Useful IFN- α dosage levels include dosages that are immunostimulatory. To determine if an IFN- α dosage is an ISD, NK lymphocyte cytotoxicity levels can be
25 measured according to the method of Whiteside et al., J. Clin. Lab. Anal., 4:102-114 (1990). Increases in the NK lymphocyte cytotoxicity levels determined according to the Whiteside method can be identified at effector cell to target cell ratios (E:T) from about 3:1 to about
30 100:1. Typically, NK lymphocyte cytotoxicity level increases are identified at E:T ratios from about 15:1 to about 50:1. Other useful E:T ratios include 3:1, 6:1, 10:1, 12:1, 15:1, 25:1, 50:1, and 100:1. Preferably, the ISD increases NK lymphocyte cytotoxicity level at least
35 about 50% compared to pretreatment NK lymphocyte

- 12 -

cytotoxicity levels, i.e., baseline NK lymphocyte cytotoxicity level. In another preferred embodiment, the ISD increases NK lymphocyte cytotoxicity at least about 75% compared to pretreatment NK lymphocyte cytotoxicity levels.

Useful IFN- α dosages range from about 500 U/m² or less to about 4,000,000 U/m². Preferred IFN- α dosages include IFN- α dosages of about 3,000,000 U/m² or less, about 1,000,000 U/m² or less, about 500,000 U/m² or less, about 250,000 U/m² or less, and about 100,000 U/m² or less. Typically, IFN- α compositions are administered via intramuscular or subcutaneous injection. However, any accepted IFN- α delivery method is within the scope of the present invention.

Useful preoperative dosage schedules include administering IFN- α for at least five days before surgical resection of a malignancy. Preferably, the dosage schedule includes administering IFN- α for five consecutive days immediately preceding surgery, with surgery being on the sixth day. More preferably, the dosage schedule includes administering a single daily dosage of IFN- α for five consecutive days immediately prior to surgery, with surgery being on the sixth day. It is to be understood, however, that other dosage schedules resulting in the appropriate immunostimulation are also within the scope of the present invention.

A hematology analysis can be performed before and after administering IFN- α dosages. Diagnostic parameters measured before administering IFN- α can be considered baseline levels of a given parameter. The hematology analysis can include three types of diagnostic tests: immunophenotyping, blood counts and NK lymphocyte cytotoxicity. To perform the hematology analysis, 25 cc of blood can be drawn from a patient in an EDTA-treated VACUTAINER (TM) tube. The blood sample can be kept at

- 13 -

room temperature until use, which is typically within two hours following collection. The blood sample can be divided into three samples: one for immunophenotyping, one for determining the blood counts and one for

5 performing the NK lymphocyte cytotoxicity assay.

Immunophenotyping includes detecting changes in NK lymphocyte numbers, NK lymphocyte function, T-lymphocyte numbers, T-lymphocyte activation, B-lymphocyte numbers and B-lymphocyte activation. Changes in immune system
10 parameters can be identified by using, for example, antibodies that recognize antigens specific to the above-identified lymphocytes according to the procedures found in the package inserts of the 1997 Beckton-Dickson Manual of Immunofluorescence. Lymphocyte phenotypic markers
15 measured include absolute numbers for CD3, CD4, CD8, CD22 and CD16/56 and the state of activation for CD25, CD22, HLA-DR, CD65 and other specific activation markers.

Blood counts include complete blood counts (CBC) and differential blood count (Diff), which can be
20 performed according to conventional clinical laboratory procedures and guidelines.

NK lymphocyte cytotoxicity can be assessed in vitro against Cr⁵¹ labeled K562 target cells according to established protocols. Whiteside et al., J. Clin. Lab.
25 Anal., 4:102-114 (1990). Briefly, peripheral blood mononuclear cells obtained by venipuncture can be purified using gradient centrifugation. The mononuclear cells can be diluted to the three different concentrations and added to radiolabeled K562 cells in
30 96-well round bottom microtiter plates. Following a 4 hr incubation at 37°C and 5% CO₂, the supernatants can be harvested and the radioactivity levels can be determined in a gamma counter (2 min counts/sample). Based on the obtained counts per minute (CPM), percent cytotoxicity
35 and lytic unit (LI) calculations may be performed in

- 14 -

accordance with conventional formulas. Changes in NK lymphocyte cytotoxicity may be determined by comparing NK lymphocyte cytotoxicity levels before and after administering IFN- α .

5 Typically, patients also undergo conventional clinical diagnostic evaluations including the following chemical parameters: absolute neutrophil count (ANC), alkaline phosphatase, aspartate transferase (AST), creatinine, direct bilirubin and total bilirubin. These
10 diagnostics are affected by IFN- α and can reflect the toxicity of IFN- α therapy. Illustrative examples of the toxicities detected by these tests include liver toxicity, kidney toxicity and bone marrow toxicity.

At times, IFN- α may produce adverse side effects
15 in patients. These side-effects typically involve flu-like symptoms. Examples of these symptoms can be found in the ALFERON-N (TM) injection package insert and accompanying material, which is available from Interferon Sciences, Inc. To monitor adverse side-effects, patients
20 can undergo a toxicity evaluation. The toxicity evaluation can measure side-effect symptoms and detect any dose limiting toxicities (DLT) experienced by a volunteer. Side-effect symptoms can be evaluated according to NCI/CTC grading scales. The symptoms to be
25 evaluated include fatigue, myalgias, anorexia, diarrhea, leukopenia, thrombocytopenia, vomiting, fevers, chills and abdominal pain. DLTs include a hematologic DLT, renal DLT or nonhematologic DLT. A hematologic DLT is defined as a grade 3 toxicity for ≥ 5 days. A renal DLT
30 is defined as serum creatine levels ≥ 2 times baseline. Nonhematologic DLT is a toxicity $\geq$ grade 3 as per Mayo/NCI Common Toxicity Criteria.

Administering an immunostimulatory dosage, as described herein, to a patient prior to undergoing
35 surgery can stimulate the patient's immune system prior

- 15 -

to surgery. Stimulating the patient's immune system prior to the patient receiving a pre-surgical anesthetic can prevent post-operative suppression of the patient's immune system. Preventing post-operative suppression of the patient's immune system can reduce the risk of postoperative infection.

An article of manufacture can include packaging material and an α -interferon composition contained within the packaging material. The α -interferon composition is effective for treating a human patient having a malignant tumor when an immunostimulatory dosage of the α -interferon composition is administered to the patient prior to surgical resection of the malignant tumor, then surgically resecting the malignant tumor. Also included with the packaging material is a label or package insert that indicates that administration of an immunostimulatory dosage of the α -interferon composition followed by surgical resection a malignant tumor is effective for treating a human patient having a malignant tumor. Any known packaging and printing method may be used to prepare the article of manufacture.

An article of manufacture can include packaging material and an α -interferon composition contained within the packaging material. The α -interferon composition is effective for treating a human patient having a malignant tumor when an immunostimulatory dosage of the α -interferon composition is administered to the patient in conjunction with effective non-surgical medical methods for diminishing malignant tumors. Also included with the packaging material is a label or package insert that indicates that administration of an immunostimulatory dosage of the α -interferon composition in conjunction with effective non-surgical medical methods for diminishing malignant tumors is effective for treating a human patient having a malignant tumor. Any known

- 16 -

packaging and printing method may be used to prepare the article of manufacture.

The invention will be further understood with reference to the following illustrative embodiments, which are purely exemplary, and should not be taken as limiting the true scope of the present invention as described in the claims.

Example 1.

Identifying an Immunostimulatory Dosage for IFN- α

10 A peripheral blood sample (7-10 cc) was obtained from a healthy volunteer in an EDTA VACUTAINER (TM) tube. The volunteer was then given a single subcutaneous 250,000 U/m² dosage of ALFERON-N (TM) (lot #01-97-06) obtained from Interferon Sciences, Inc. The next day
15 (18-24 hours post ALFERON-N (TM) dosage) a 7-10 cc peripheral blood sample was withdrawn using an EDTA VACUTAINER (TM) tube.

NK lymphocyte cytotoxicity levels were assessed in vitro for both blood samples. NK cell cytotoxicity was
20 determined using CR⁵¹ labeled K562 target cells according to the methods of Whiteside et al., J. Clin. Lab. Anal. 4:102 (1990). Briefly, peripheral blood mononuclear cells were isolated by gradient centrifugation (Ficol Hypaque, 1077, Sigma Chem. Co., St. Louis, MO). The
25 mononuclear cells were diluted and added to Cr⁵¹ radiolabeled K562 cells in 96 well round bottom microtiter plates. The cell mixture was incubated for four (4) hours at 37°C and 5% CO₂. Supernatants resulting from the incubation were harvested using a SKATRON (TM)
30 supernatant harvester. The radioactivity levels of the supernatants were quantitated for 2 minutes per sample in a gamma counter. The counts per minute (cpm) percent cytotoxicity for each supernatant sample was computed.

- 17 -

NK lymphocyte cytotoxicity was assessed at effector:target ratios (E:T ratio), i.e., mononuclear cell:K562 cell ratio, of 3:1, 6:1, 12:1, 25:1, 50:1, and 100:1. At a 3:1 effector:target ratio the baseline (pre-ALFERON-N (TM) dosage) NK lymphocyte cytotoxicity level was 0.8%. At a 25:1 effector:target ratio, the basal NK lymphocyte cytotoxicity level was 26%. At a 3:1 effector:target ratio, the NK lymphocyte cytotoxicity level was 5.5% for the NK lymphocytes harvested one day after the 250,000 U/m² ALFERON-N (TM) dosage. At a 25:1 effector:target ratio, the post-ALFERON-N (TM) dosage NK lymphocyte cytotoxicity level was 28.6%. The NK lymphocyte cytotoxicity level increase at the 25:1 ratio was 10% $((28.6\%/26\%)-1)*100$. Graphical representations of the baseline and IFN- α stimulated NK lymphocyte cytotoxicity levels at E:T ratio of 3:1 and 25:1 are shown in FIG. 1. Graphical results for other E:T ratios measure NK lymphocyte cytotoxicity levels are shown in FIG. 2.

20

Example 2.Identifying an Immunostimulatory Dosage for IFN- α

The volunteer of Example 1 was given a single subcutaneous 500,000 U/m² dosage of ALFERON-N (TM) (lot #01-97-06) seven days after receiving the ALFERON-N (TM) dosage of Example 1. Seven days was sufficient time to allow for the volunteer's baseline NK lymphocyte cytotoxicity level to return to the baseline levels of Example 1. The next day (18-24 hours post ALFERON-N (TM) dosage) a 7-10 cc peripheral blood sample was withdrawn using an EDTA VACUTAINER (TM) tube.

30

NK cell function was assessed in vitro for the blood sample. NK cell cytotoxicity was determined using CR⁵¹ labeled K562 target cells according to the methods of

- 18 -

Whiteside et al., J. Clin. Lab. Anal. 4:102 (1990), as described in Example 1.

At a 3:1 effector:target ratio, the post 500,000 U/m² ALFERON-N (TM) dosage NK lymphocyte cytotoxicity level was 8%. At a 25:1 effector:target ratio, the post 500,000 U/m² ALFERON-N (TM) dosage NK lymphocyte cytotoxicity level was 39.8%. The NK lymphocyte cytotoxicity level increase at the 25:1 ratio was 53% $((39.8\%/26\%)-1)*100$. The NK lymphocyte cytotoxicity levels for the results of Example 2 are also indicated in FIG. 1 and FIG. 2.

Example 3.
Identifying an Immunostimulatory Dosage for IFN- α

Six to sixty volunteers are entered into two independent phase I trials to identify an immunostimulatory dosage (ISD) and observe any toxicities for ALFERON-N (TM). For purposes of the study, an ISD for ALFERON-N (TM) is the ALFERON-N (TM) dosage that increases NK lymphocyte cytotoxicity levels at least about 50% above the NK lymphocyte cytotoxicity levels measured prior to administration of ALFERON-N (TM) in at least two out of three volunteers evaluated at a given ALFERON-N (TM) dosage level.

Volunteers can consist of two groups: 1) healthy individuals and 2) volunteers who have a history of resected malignant melanoma. Melanoma volunteers should have been disease free for at least four months but less than five years.

Eligible volunteers should be at least 18 years of age, have a life expectancy greater than 12 weeks and be willing to return for a follow-up examination. Eligible volunteers can be selected to fall within the following clinical diagnostic parameters: ANC $\geq$ 1500/ μ L, platelet

- 19 -

counts $\geq 100,000/\mu\text{L}$, alkaline phosphatase $\leq 3 \times \text{UNL}$, AST $\leq 3 \times \text{UNL}$, Creatinine $\leq 1.5 \times \text{UNL}$ and Total Bilirubin.

Eligible volunteers also should not have or have had a Eastern Co-operative Oncology Group performance status (ECOG) status 3 or 4, and should not have had an uncontrolled infection, chemotherapy ≤ 4 weeks, mitomycin C/nitrosoureas ≤ 6 weeks, immunotherapy ≤ 4 weeks, biologic therapy ≤ 4 weeks, radiation therapy ≤ 4 weeks, radiation to $>25\%$ of bone marrow, or treatment with antibiotics or antihistamines ≤ 4 weeks. In addition, failure to fully recover from the effects of prior chemotherapy regardless of interval since last treatment disqualifies a volunteer. The following conditions can also disqualify a volunteer: New York Heart Association classification of III or IV, CNS metastases, a seizure disorder, pregnancy, presently lactating, other concurrent chemotherapy, other concurrent immunotherapy, other concurrent radiotherapy, current evidence of malignancy, known chronic medical/psychiatric illnesses (such as diabetes, cirrhosis, chronic psychiatric conditions), known recent acute illnesses (including infections, allergic reactions, and autoimmune conditions) within the last 4 weeks, current/chronic use of medications, or known hypersensitivity to egg protein or neomycin.

Five eligible volunteers are entered at each dosage level, which is assigned according to Table 1. The first level evaluated is the $10,000 \text{ U/m}^2$ dosage (level 4). A dose escalation model is used to identify the ISD for ALFERON-N (TM) by proceeding step-wise up the dosage scale. That is, after the first five volunteers are evaluated, the next five volunteers enter at the next higher dosage level and so on.

- 20 -

Table 1. ALFERON-N (TM) Dosages
Dosage Level ALFERON-N (TM) U/m²

	1	500
	2	1000
5	3	5000
	4	10,000
	5	50,000
	6	100,000
	7	250,000
10	8	500,000
	9	1,000,000
	10	2,000,000
	11	4,000,000

Each eligible volunteer entering the study
 15 undergoes a complete medical history, a standard physical
 examination including height, weight and performance
 status (PS), blood count, and clinical diagnostic
 chemistry evaluation within fourteen days preceding the
 volunteer's first ALFERON-N (TM) treatment. In addition
 20 to above-identified treatment, women volunteers of child
 bearing potential also undergo a serum pregnancy test
 within seven days prior to beginning the treatment
 schedule.

On day 1, each volunteer undergoes a hematology
 25 analysis, and then receives the volunteer's assigned
 intramuscular dosage of ALFERON-N (TM). On days 2 and 3
 (24 and 48 hours post ALFERON-N (TM) treatment), each
 volunteer undergoes a hematology analysis, physical
 examination and a toxicity evaluation. Increases in NK
 30 lymphocyte cytotoxicity levels can be determined by
 comparing NK lymphocyte cytotoxicity levels measured on
 day 1 with the NK lymphocyte cytotoxicity levels measured
 on days 2 or 3. Two weeks after receiving ALFERON-N
 (TM), each volunteer receives another medical exam, blood
 35 count, creatinine clinical evaluation, and toxicity
 evaluation.

If a volunteer fails to complete the initial
 course of therapy, i.e., ALFERON-N (TM) administration

- 21 -

and follow-up testing with 2 week observation, for any reason, the volunteer is regarded as treatment intolerant and an additional volunteer is treated at that dosage level.

- 5 Unless significant toxicities are observed, dose escalation continues until all dosage levels are exhausted. Significant toxicities are observed when 3 out of the 5 volunteers at a given dosage level experience a DLT. This dose escalation model creates an
- 10 ALFERON-N (TM) dosage versus NK lymphocyte cytotoxicity level response curve, which facilitates identifying the optimal ALFERON-N (TM) dosage.

Example 4.

Identifying an Optimal Individualized IFN- α ISD

- 15 A patient who has a documented early-stage solid tumor has their baseline NK lymphocyte cytotoxicity level assessed as described above. Next, a single immunostimulatory dosage of ALFERON-N (TM) identified in Example 3 is administered to the patient. The patient's
- 20 NK lymphocyte cytotoxicity level is again assessed twenty four hours following ALFERON-N (TM) administration.

- If the patient's NK lymphocyte toxicity levels are at least about 50% higher than the patient's baseline NK lymphocyte cytotoxicity levels at an E:T ratio of 25:1,
- 25 then the identified dosage is considered the individual's optimized ALFERON-N (TM) dosage. If the ALFERON-N (TM) dosage resulted in less than a 50% increase in NK lymphocyte cytotoxicity level, the patient is administered a second ALFERON-N (TM) dosage that is 2
- 30 standard deviations less than the mean ISD ALFERON-N (TM) dosage identified in Example 3. The second ALFERON-N (TM) dosage is administered after a five day wash-out period. If the second dosage is unsuccessful, the patient is administered a third ALFERON-N (TM) dosage

- 22 -

that is 2 standard deviations more than the mean ISD ALFERON-N (TM) dosage. The third ALFERON-N (TM) dosage is also administered after a five day wash-out period. If the third ALFERON-N (TM) dosage does not result in at least about a 50% increase in NK lymphocyte cytotoxicity level, the ALFERON-N (TM) dosing is repeated at 1 standard deviation below and above the mean ISD ALFERON-N (TM) dosage identified in Example 3. Again, each dosing test is performed after a 5 day wash-out period. If the final treatment schedule does not result in at least about a 50% increase in NK lymphocyte cytotoxicity level, the patient is considered not to have an optimal ALFERON-N (TM) dosage.

Example 5.

15 Treating Patients with Immunostimulatory Dosages of IFN- α

Having identified an optimal ALFERON-N (TM) ISD, a patient suffering from a early-stage resectable malignancy is administered five injections of the optimal ALFERON-N (TM) dosage once per day for five days immediately prior to surgery. On the sixth day, the resectable malignancy is surgically resected according to accepted medical techniques. Post-operative hematology analysis is performed as described herein on days 1 and 7 following surgery. Thereafter, continued monitoring of the patient's progress is performed at regularly scheduled checkups every three months following surgery. In addition, post-operative monitoring and continued monitoring provides information concerning the incidence of post-operative infections in the patients, which can be reduced in patients receiving the immunostimulatory dosages of IFN- α as disclosed herein.

Other aspects, advantages, and modifications are within the scope of the following claims.

Where the terms “comprise”, “comprises”, “comprised” or “comprising” are used in this specification, they are to be interpreted as specifying the presence of the stated features, integers, steps or components referred to, but not to preclude the presence or addition of one or more other feature, integer, step, component or group thereof.

5



- 23 -

What is claimed is:

1. Use of an α -interferon composition in the manufacture of a medicament for the treatment of a human patient having a resectable malignant tumor,
5 wherein said medicament is administered in an immunostimulatory dosage to said patient before surgically resecting said malignant tumor.
 2. The use of claim 1 wherein said immunostimulatory dosage is about 3,000,000 U/m² per day or less.
 - 10 3. The use of claim 1 wherein said immunostimulatory dosage is about 1,000,000 U/m² per day or less.
 4. The use of claim 1 wherein said immunostimulatory dosage is about 500,000 U/m² per day or less.
 5. The use of claim 1 wherein said immunostimulatory
15 dosage is about 250,000 U/m² per day or less.
 6. The use of claim 1 wherein said immunostimulatory dosage is about 100,000 U/m² per day or less.
 7. The use of claim 1 wherein said immunostimulatory dosage is administered for about five days before
20 resecting said malignant tumor.
 8. The use of claim 7 wherein said immunostimulatory dosage is administered once per day.
 9. The use of claim 7 wherein said immunostimulatory dosage increases NK lymphocyte cytotoxicity at
25 least about 50% above the NK lymphocyte cytotoxicity measured before administering said dosage.
-

- 24 -

10. The use of claim 9 wherein said NK lymphocyte cytotoxicity is measured at an effector to target cell ratio from about 15:1 to about 50:1.
- 5 11. The use of claim 7 wherein said immunostimulatory dosage increases NK lymphocyte cytotoxicity at least about 75% above the NK lymphocyte cytotoxicity measured before administering said immunostimulatory dosage.
- 10 12. The use of claim 11 wherein said NK lymphocyte cytotoxicity is measured at an effector to target cell ratio from about 15:1 to about 50:1.
13. The use of claim 7 wherein said immunostimulatory dosage increases B-lymphocyte activation.
- 15 14. The use of claim 7 wherein said immunostimulatory dosage increases B-lymphocyte function.
15. The use of claim 7 wherein said immunostimulatory dosage increases T-lymphocyte activation.
16. The use of claim 7 wherein said immunostimulatory dosage increases T-lymphocyte function.
- 20 17. The use of claim 1 wherein said malignant tumor is a solid tumor.
18. The use of claim 17 wherein said solid tumor is selected from the group consisting of breast cancer, lung cancer, pancreatic cancer, brain
25 cancer, prostate cancer, ovarian cancer, uterine cancer, renal cancer, and melanoma.

19. The use of Claim 18 wherein said solid tumor is an early-stage solid tumor.

20. The use of Claim 17 wherein said solid tumor is an early-stage solid tumor.

5 21. The use of Claim 1 wherein said malignant tumor is a melanoma.

22. The use of Claim 1 wherein said malignant tumor is a renal carcinoma.

23. Use of an α -interferon composition in the manufacture of a
10 medicament for preventing post-operative infection, wherein said medicament is administered in an immunostimulatory dosage to a human before surgery.

24. An article of manufacture comprising packaging material and an α -interferon composition contained within said packaging material, wherein said packaging material comprises a label or package insert indicating that

15 administration of an immunostimulatory dosage of said α -interferon composition followed by surgical resection of a malignant tumor can be effective for treating a human patient having said malignant tumor, when used in a method for treating a human patient having a resectable malignant tumor, comprising administering an immunostimulatory dosage of an α -interferon composition to said patient, then
20 surgically resecting said malignant tumor, wherein said immunostimulatory dosage is about 4,000,000 U/m² per day or less.

25. An article of manufacture comprising packaging material and an α -interferon composition contained within said packaging material, wherein said packaging material comprises a label or package insert indicating that

25 administration of an immunostimulatory dosage of said α -interferon composition in conjunction with treating said patient using effective non-surgical medical methodologies for diminishing said malignant tumor can be effective for treating a human patient having said malignant tumor, when used in a method for treating a human patient having a malignant tumor, comprising administering an
30 immunostimulatory dosage of an α -interferon composition to said patient, then treating the patient using effective non-surgical medical methodologies for diminishing the malignant tumour, wherein said immunostimulatory dosage is about 1,000,000 U/m² per day or less.



26. Use of an α -interferon composition in the manufacture of a medicament for the treatment of a human patient having a non-resectable malignant tumor, wherein said medicament is administered in an immunostimulatory dosage to said patient wherein said immunostimulatory dosage is about 1,000,000 U/m² per day or less, and wherein said patient is treated with effective non-surgical medical methodologies to diminish said tumor.

27. A method for treating a human patient having a resectable malignant tumor, comprising administering an immunostimulatory dosage of an α -interferon composition to said patient, then surgically resecting said malignant tumor, wherein said immunostimulatory dosage is about 4,000,000 U/m² per day or less.

28. A method for treating a human patient having a non-resectable malignant tumour, comprising administering an immunostimulatory dosage of α -interferon to said patient and then treating said patient with effective non-surgical medical methodologies to diminish said tumor wherein said immunostimulatory dosage is about 1,000,000 U/m² per day or less.

29. Use of an α -interferon composition in the manufacture of a medicament for the treatment of a human patient having a resectable malignant tumor, wherein said medicament is administered in an immunostimulatory dosage to said patient before surgically resecting said malignant tumor substantially as herein described with reference to the accompanying Examples.

30. Use of an α -interferon composition in the manufacture of a medicament for preventing post-operative infection, wherein said medicament is administered in an immunostimulatory dosage to a human before surgery substantially as herein described with reference to the accompanying Examples.

31. An article of manufacture comprising packaging material and an α -interferon composition contained within said packaging material, wherein said packaging material comprises a label or package insert indicating that administration of an immunostimulatory dosage of said α -interferon composition followed by surgical resection of a malignant tumor can be effective for treating a human patient having said malignant tumor, when used in a method for treating a human patient having a resectable malignant tumor, comprising administering an immunostimulatory dosage of an α -interferon composition to said patient, then



surgically resecting said malignant tumor, wherein said immunostimulatory dosage is about 4,000,000 U/m² per day or less substantially as herein described with reference to the accompanying Examples.

32. An article of manufacture comprising packaging material and an
5 α -interferon composition contained within said packaging material, wherein said packaging material comprises a label or package insert indicating that administration of an immunostimulatory dosage of said α -interferon composition in conjunction with treating said patient using effective non-surgical medical methodologies for diminishing said malignant tumor can be effective for treating a
10 human patient having said malignant tumor, when used in a method for treating a human patient having a malignant tumor, comprising administering an immunostimulatory dosage of an α -interferon composition to said patient, then treating the patient using effective non-surgical medical methodologies for diminishing the malignant tumour, wherein said immunostimulatory dosage is
15 about 1,000,000 U/m² per day or less substantially as herein described with reference to the accompanying Examples.

33. Use of an α -interferon composition in the manufacture of a medicament for the treatment of a human patient having a non-resectable malignant tumor, wherein said medicament is administered in an
20 immunostimulatory dosage to said patient wherein said immunostimulatory dosage is about 1,000,000 U/m² per day or less, and wherein said patient is treated with effective non-surgical medical methodologies to diminish said tumor substantially as herein described with reference to the accompanying Examples.

34. A method for treating a human patient having a resectable
25 malignant tumor, comprising administering an immunostimulatory dosage of an α -interferon composition to said patient, then surgically resecting said malignant tumor, wherein said immunostimulatory dosage is about 4,000,000 U/m² per day or less substantially as herein described with reference to the accompanying Examples.

30 35. A method for treating a human patient having a non-resectable malignant tumour, comprising administering an immunostimulatory dosage of α -interferon to said patient and then treating said patient with effective non-surgical medical methodologies to diminish said tumor, wherein said immunostimulatory



dosage is about 1,000,000 U/m² per day or less substantially as herein described with reference to the accompanying Examples.

36. A method of preventing post-operative infection in a patient comprising administering an immunostimulatory dosage of α -interferon to the
- 5 patient before surgery.


DATED this 30th day of April, 2001

10

MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH

By their Patent Attorneys:

CALLINAN LAWRIE



Michael J. Houlihan.



Fig. 1

EFFECTS OF ALFERON N in vivo ON HUMAN NK
CYTOTOXICITY MEASURED 24H AFTER Rx
(IFN = 250,000 U/m²; IFN 2 = 500,000 U/m²)




Fig. 2
EFFECTS OF ALFERON-N in vivo (250,000 U/m²) ON
HUMAN NK CYTOTOXICITY MEASURED 24H AFTER Rx

